Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2014

View Archived Issues

Bayer presents first-in-human and promising in vivo data for BAY-85-8501

Discovery of novel allosteric GSK-3 inhibitors for the treatment of neurodegenerative diseases

Sanofi and MyoKardia form collaboration to develop treatments for genetic cardiomyopathies

Genzyme product receives orphan designation for Gaucher's disease

Legalon Sil given FDA orphan designation for amatoxin poisoning

BA-321, a selective androgen receptor modulator for treatment of male osteoporosis

Cell Cure Neurosciences shows safety and efficacy of OpRegen in animal studies

Metabolon partners with Metdia for European commercialization of prediabetes tests

Sutro Biopharma and Merck KGaA establish ADC collaboration agreement

Glenmark completes phase IIa study of TRPA1 receptor antagonist

USP7 gene polymorphisms linked to breast cancer susceptibility in Chinese women

World Alzheimer's Day: Research efforts towards early diagnosis and new therapeutic strategies

Research looks into role of betatrophin in human diabetes and its potential as a biomarker

Shionogi discloses novel AMPK activators for diabetes

Avraham Pharmaceuticals raises additional funding to advance ladostigil development

Mochida Pharmaceutical synthesizes new PDE10 inhibitors

Janssen patents novel compounds for HBV infection

Scientists at Bristol-Myers Squibb disclose new agents for cancer

Therabiol divulges new vaccines for HIV infection

Pocket consortium updates on tuberculosis diagnostic device

Zydelig approved in E.U. for chronic lymphocytic leukemia and follicular lymphoma

Fred Hutchinson Cancer Research Center receives grant to run infection epidemiology center

Umecrine Mood reports results from phase I/II trial of UC-1010

Japanese approval of Eylea for myopic choroidal neovascularization

Nuvilex advances Cell-in-a-Box programs for pancreatic cancer and diabetes

Qu Biologics closes private financing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...